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ABSTRACT
Recently, there has been a move encouraged by many stakeholders towards generating
big, open data in many areas of research. One area where big, open data is particularly
valuable is in research relating to complex heterogeneous disorders such as Autism
Spectrum Disorder (ASD). The inconsistencies of findings and the great heterogeneity
of ASD necessitate the use of big and open data to tackle important challenges such as
understanding and defining the heterogeneity and potential subtypes of ASD. To this
end, a number of initiatives have been established that aim to develop big and/or open
data resources for autism research. In order to provide a useful data reference for autism
researchers, a systematic search for ASD data resources was conducted using the Scopus
database, the Google search engine, and the pages on ‘recommended repositories’ by
key journals, and the findings were translated into a comprehensive list focused on
ASD data. The aim of this review is to systematically search for all available ASD data
resources providing the following data types: phenotypic, neuroimaging, human brain
connectivitymatrices, humanbrain statisticalmaps, biospecimens, andASDparticipant
recruitment. A total of 33 resources were found containing different types of data
from varying numbers of participants. Description of the data available from each
data resource, and links to each resource is provided. Moreover, key implications are
addressed and underrepresented areas of data are identified.
Subjects Bioinformatics, Neuroscience, Psychiatry and Psychology
Keywords Autism spectrum disorder, ASD, Data sharing, Open science, Subtyping, Heteroge-
neous disorders, Databases, Neuroimaging data, Phenotypic data, Biobanks
INTRODUCTION
Recently, there has been a move towards generating ‘big’ and ‘open’ data in many areas
of science such as psychology, neuroscience, genetics, and omics. The move is driven by
many stakeholders involved in the academic research process, including funding bodies,
publishers, researchers, and participants. Funding bodies (including the Medical Research
Council, the Wellcome Trust, and the US National Institutes of Health (NIH), among
others) are increasingly funding large studies and initiatives that facilitate data sharing.
In addition, their data-policies are recommending and, in certain cases, requiring the
studies that they fund to submit a data-sharing plan and to share their data. Publishers are
also playing a role in driving big data and data sharing efforts through their data policies,
data-oriented special issues and call for papers (e.g., Focus on Big Data, 2014; Eickhoff et
al., 2016), and the launch of machine-readable data journals (e.g., Scientific Data and
GigaScience). Depending on the data type and the journal, researchers are expected to
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make their data available either at the time of publication or after an embargo period.
Researchers are also playing a role by getting involved in data-sharing initiatives. Some
are increasingly preparing their data for sharing (e.g., through proper data management
and annotation) and/or requesting access to data from others for secondary analysis.
Although participants have concerns about data-sharing policies, many are also supportive
of this drive and are participating in studies and initiatives that ask them to consent for
their data to be used and shared somewhat flexibly to different researchers and studies
(Oliver et al., 2012; Cummings, Zagrodney & Day, 2015).
‘Big data’ is an evolving term and its use to refer to data in the mentioned areas is
relatively new. Therefore, in this review, the term ‘big data’ is used to broadly refer to
datasets that are larger than what researchers conventionally handle in their respective
fields. While ‘open data’ refers to data that is available for researchers to access without a
fee or with a reasonable fee relative to the many costs of collecting data (e.g., funds, time,
resources, etc.)
One area where big data is particularly valuable is in research relating to complex
heterogeneous disorders such as Autism SpectrumDisorder (ASD). ASD is a heterogeneous
neurodevelopmental disorder (or spectrum of disorders, (see Geschwind & Levitt, 2007))
that is diagnosed based on a dyad of core behavioural symptoms of social communication
deficits and characteristic repetitive and restricted behaviour (American et al., 2013).
Although these two core symptom domains somewhat unify and define ASD, there is
significant variability between people with ASD in terms of symptom severity, symptom
profile, level of cognitive function, and comorbidities (Hewitson, 2013). This heterogeneity
is potentially a major factor impacting on the rate of replication of ASD studies, and is
leading some researchers to ‘‘give up on a single explanation for autism’’ (Happé, Ronald &
Plomin, 2006) and others to propose the possibility that ASD should not be considered as
a single disorder (Geschwind & Levitt, 2007). Instead, they suggest that within ASD, there
could be groups of distinct disorders with many aetiologies (Geschwind & Levitt, 2007).
Given that the cause, the aetiology and the genetic landscape of ASD remain unknown,
developing a clear picture of exactly what ASD is, and what it is not, is increasingly
important.
Indeed, ASD is phenotypically heterogeneous between and within affected individuals
who show varying trajectories and response to treatment (Fountain, Winter & Bearman,
2012; Gotham, Pickles & Lord, 2012; Venker et al., 2014). Heterogeneity is also implied in
ASD’s genetic architecture: non-overlapping genetic risk factors are continuing to reveal
locus and allelic heterogeneity. Many different genes are involved with ASD and the
genetic findings seem to vary depending on numerous factors such as the sample’s
phenotypic profile, gender (Werling & Geschwind, 2013), pedigree (e.g., simplex or
multiplex families) (Sebat et al., 2007; Marshall et al., 2008), and sample size, etc. With
the advent of next generation sequencing techniques, the number of genes found that
are associated with ASD is increasing to over 800 genes (Banerjee-Basu & Packer, 2010);
consequently, it is becoming even more challenging to find unified explanations and
functional associations between the genes involved. Thus, the unique nature of ASD’s
heterogeneity and the current state of autism research highlights the importance of
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investigating the possibility that ASD may be a disorder with different subtypes, which
have distinct phenotypic, cognitive, and/or genetic profiles.
A number of studies have attempted to define the subtype structure of ASD by searching
for empirically derived clusters of participants within relatively large datasets. The majority
of work in this area has taken a phenotype-first approach, i.e., by attempting to identify
potential ASD subtypes by clustering participants based on behavioural, cognitive or
medical characteristics (Cholemkery et al., 2016; Georgiades et al., 2013; Doshi-Velez, Ge &
Kohane, 2014). In some cases, attempts have been made to demonstrate the convergent
validity of these potential subtypes using genetic data (Liu et al., 2011; Veatch et al., 2014).
However, this work has yielded varying findings with regard to the number of identified
subgroups, the classification of phenotypes, and the resulting identified genes or loci. For
example, the number of proposed potential subgroups varies from two (Veatch et al., 2014;
Vieland et al., 2011), three (Cholemkery et al., 2016;Wiggins et al., 2012), four (Doshi-Velez,
Ge & Kohane, 2014; Liu et al., 2011; Veatch et al., 2014; Vieland et al., 2011; Wiggins et al.,
2012; Kim et al., 2016;Hu & Steinberg, 2009), to six (Greaves-Lord et al., 2013). In addition,
there is no agreed description of subtype markers for ASD as there are many relevant
possible categories and specifiers (Lai et al., 2013); potential candidates include: symptom
severity (Cholemkery et al., 2016; Georgiades et al., 2013; Veatch et al., 2014; Wiggins et
al., 2012; Hu & Steinberg, 2009), insistence on sameness scores (Hus et al., 2007; Bishop
et al., 2013), IQ scores (Vieland et al., 2011; Liu, Paterson & Szatmari, 2008), sensory
features (Ausderau et al., 2014; Uljarević et al., 2016), and ASD comorbidities (Doshi-
Velez, Ge & Kohane, 2014). Although stratification attempts have been shown to improve
statistical power in individual genetic studies, e.g., leading to higher LOD scores in linkage
studies (Liu, Paterson & Szatmari, 2008; Buxbaum et al., 2001; Shao et al., 2003), replicable
findings are somewhat rare such that different studies find different sets of ASD-implicated
genes and loci (e.g., Liu, Paterson & Szatmari, 2008; Buxbaum et al., 2001; Shao et al.,
2003). In addition, Chaste et al. (2015) found that phenotypic stratification had only a
small effect on increasing power and the homogeneity of genetic findings. However in this
case phenotypic stratification was based on rather broad, and univariate characteristics
such as symptom severity, IQ and diagnostic category, which, in isolation, may not be
representative subtype markers.
Contrary to the phenotype-first approach, the genotype-first approach is driven by a
reverse strategy in which participants are grouped and studied based on a shared genetic
etiology (e.g., a specific CNV or gene associated with a disorder) as opposed to a common
phenotypic or clinical profile (e.g., language impairment, ASD diagnosis) (Stessman,
Bernier & Eichler, 2014; Stessman, Turner & Eichler, 2016). Following the identification of a
genetically homogenous group, assessments are made to deeply characterize the respective
group (i.e., phenotypic characterization and otherwise) and understand its association with
the relevant disorders if applicable. Among the recent studies related to the ASD subtyping
literature are those supported and facilitated by the Simons Foundation Autism Research
Initiative (SFARI), which adopted the genotype-first approach to studying individuals with
16p11.2CNVs (a recurrent CNV significantly associatedwithASD) (see Simons Foundation,
2016; Consortium, 2012). Deep characterization of 16p11.2 CNV carriers whether through
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examining their phenotypic and clinical features (e.g., Hanson et al., 2015; Steinman et al.,
2016), electrophysiological brain activity as recorded with M/EG (e.g., Jenkins et al., 2016;
Leblanc & Nelson, 2016), or otherwise (e.g., Qureshi et al., 2014; Chang et al., 2016) would
ultimately establish whether a particular genetically homogenous group could be regarded
as an empirically-derived ASD subtype. As of yet, the ASD subtyping literature, phenotype-
and genotype-centric, is growing and advancing in its approach and methodology to
investigating ASD potential subtypes; this is largely due to consortia and data resources
sharing ASD and ASD-related data to the research community.
Although this is not meant to be a comprehensive review of the ASD heterogeneity/
subtyping literature, from the aforementioned studies and findings it could suggest that
successful identification of potential ASD subtypes, if they are to be found, requires data
from large numbers of participants who are drawn from a wide sample of the autism
spectrum. The task of assembling such a cohort may often be unfeasible for a single
researcher, or team of researchers, to accomplish. Therefore, motivated, in part, by the role
that big, and open, data can play in defining the typology of ASD, and in understanding the
neural aetiology and genetic origin of ASD, a number of initiatives have been established,
primarily in the USA, that aim to develop big data resources for autism research. One
example is SFARI, which is an ASD data resource that shares data from large numbers of
specific phenotypic and genetic profiles of participants, and allows different researchers
with different expertise to conduct various analyses on the same sample (e.g., Hudac et al.,
2015). In addition to the large datasets provided by SFARI, numerous other open ASD
datasets exist for use by the research community.
The aim of this article is to identify and describe available resources that provide access
to data obtained from participants with ASD. Several existing reviews have accumulated
a general list of available data resources, although these are not ASD-specific (Van Horn
et al., 2004; Van Horn et al., 2005; Van Horn & Toga, 2009; Ferguson et al., 2014; Poldrack
& Gorgolewski, 2014). Although useful, these lists are non-comprehensive and are mainly
limited to neuroimaging resources. In addition, some of the lists included resources that are
inaccessible to researchers (e.g., limited access data to only respective consortia members),
and thus would not be beneficial to the research community at large. Most importantly,
to date, no detailed list of available sources of ASD data exists. Therefore, in order to
provide a useful data reference for autism researchers, a systematic search was conducted,
and the findings were translated into a comprehensive list focused on ASD data. A total
of 33 resources were found containing different types of data from varying numbers of
participants. Description of the data available from each data resource, and links to each
resource is provided. Moreover, key implications are addressed and underrepresented areas
of data are identified.
METHODOLOGY
Our aim was to conduct the equivalent of a systematic review, which in this paper is
described as a ‘systematic search’. Therefore, wherever possible, the search for ASD
resources closely followed the guidelines and the layout of a systematic literature review, and
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Table 1 Search terms.
Keywords Database/Search
engine
# of results on
primary search
Autism AND (database OR databank OR repository) Scopus 1,050 results
Autism AND (database OR databank OR repository) Googlea ∼14,400,000 results
Autism AND data AND sharing Scopus 80 results
Autism AND data AND sharing Googlea ∼6,310,000 results
Autism AND (database OR databank OR repository) AND
(EEG ORMEG)
Scopus 19 results
Autism AND (database OR databank OR repository) AND
(EEG ORMEG)
Googlea ∼515,000 results
Autism AND (database OR databank OR repository) AND
MRI
Scopus 23 results
Autism AND (database OR databank OR repository) AND
MRI
Googlea ∼354,000 results
Autism AND (database OR databank OR repository) AND
(genetic OR genome)
Scopus 315 results
Autism AND (database OR databank OR repository) AND
(genetic OR genome)
Googlea ∼493,000 results
Autism AND (database OR databank OR repository) AND
(phenotype OR phenotypic)
Scopus 145 results
Autism AND (database OR databank OR repository) AND
(phenotype OR phenotypic)
Googlea ∼524,000 results
Notes.
aOnly pages one to three (inclusive) were assessed.
the methodology followed a rigorous structure and search process. The search strategy was
performed by the author, Reem Al-jawahiri. The principal focus of the search was datasets
containing data pertaining to symptom severity and symptom profile (e.g., scores on the
Autism Diagnostic Observational Schedule (ADOS), or Autism Diagnostic Inventory-
Revised (ADI-R), cognitive ability, neuroimaging and biospecimens. We used a number
of key-word combinations to identify these resources (see Table 1). While carrying out
the search we also identified a number of sources of available genetics and omics data;
some of which contained data from participants with ASD, others contained genetic or
omics data useful for the study of ASD.Where information about these datasets was readily
available on the relevant webpage these data sources have also been included and described
here. However, where information about the datasets was less clear, either because it
was not readily available via the website, or because it required specialist knowledge to
understanding the nature of the material held by the dataset, these resources were not
included.
Search terms
The combinations of search terms used, and the number of results returned from either
Scopus or Google for each search term are presented in Table 1.
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Inclusion and exclusion criteria
Available data resources that share human ASD data of numerous types including
phenotypic, neuroimaging, human brain connectivity matrices, human brain statistical
maps, biospecimens, and ASD participant recruitment services were considered eligible
for inclusion. Data types, including datasets, databases, databanks, data repositories,
institutions offering subject recruitment services, and big-data-initiatives that are currently
sharing or have made a public statement of intent to share ASD data at a point in time, were
considered eligible regardless of methodology and modality of data collection and analysis.
Resources of electronic medical records, clinical trial registries, and data relating to animal
studies were excluded. In order to avoid redundant data and clutter, if more than one
source housed the same ASD dataset then only the original dataset source or key website
was included. Within Scopus, the title, abstract, and keywords of the returned articles were
searched using the key search terms. Only articles or webpages written in English were
included. The search was carried out between January and March 2016, therefore any new
data resources or initiatives made available after March 2016 are not included.
Search process
The Google search engine and the Scopus electronic database were systematically
searched for relevant ASD data resources. The search terms and the different search
term combinations used are listed in Table 1. Because Google is a search engine (and not
a database with limited results), only pages one to three, inclusive, were assessed; After the
third page, the links become less relevant and therefore the limit was set to comprise the
first three pages. Naturally, in the case of Scopus searches, all results were assessed. The
results in Scopus are based on searches of the search terms in the title/abstract/keywords
of the identified journal articles.
Relevant metadata articles, bioinformatics articles, and relevant data portals were also
identified and were useful to further complete the data search. Some articles described
the data resources or datasets, while others presented tables of useful resources for data
access and sharing - although not specifically referring to ASD data (i.e., Van Horn et
al., 2004; Van Horn et al., 2005; Van Horn & Toga, 2009; Ferguson et al., 2014; Poldrack &
Gorgolewski, 2014). The Neuroimaging Informatics Tools and Resources Clearinghouse,
Neuroscience Information Framework, and SciCrunch are among the data portals and
registries used in the systematic search for relevant data resources. Further articles/data
resourceswere found through cited reference searching and through the ‘related documents’
option in the Scopus database.
The ‘information for authors’ section of a number of journals, including Nature
publishing group journals, Scientific Data journal, PLOS journals, BioMed Central/
GigaScience journal were examined for whether requirements or recommendations were
expressed regarding the assimilation of data via supplementary information or via particular
data resources/repositories. These journals provided lists of recommended data resources
for particular data types for authors wishing to submit their manuscripts and related data.
The ‘policy’ tab of the Wellcome Trust provided a similar, useful list of data resources.
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Based on titles, potentially relevant articles or webpages were identified and grouped in
tabs, before either the abstract or the webpage of all the saved tabs was assessed. Articles
and webpages that consisted of items fitting the inclusion criteria were further assessed
after accessing the full text versions and finding the relevant websites of the data resources.
Some data providers were contacted for further verification regarding the data type and
availability. Duplicates of links leading to the same data resources found from searches,
were removed. Similarly, as mentioned earlier, websites hosting the same ASD datasets or
overlapping datasets were removed to avoid clutter.
RESULTS
A total of 33 data resources that provide ASD data were identified. Links to these resources,
and a description of the data they hold can be seen in Tables 2 and 3 (in addition to the
supporting information in File S1). In both tables, the resources are ordered based on two
criteria and the first criterion takes precedent over the second. The first criterion is whether
they specialize in only ASD data as opposed to also providing data from other populations
in addition to the ASD data. For example, for Table 2, since the National Database for
Autism Research (NDAR), SFARI, Autism Genetic Resource Exchange (AGRE), Autism
Spectrum Database-UK (ASD-UK), and Interactive Autism Network (IAN) all specifically
and solely provide ASD data, they are positioned at the top of the list. The second criterion
is based on the similarity (among the resources in the respective table) in the general ASD
data-type they handle and provide. For example, Autism Brain Imaging Data Exchange
(ABIDE) and the Australian EEG Database (AED) both mainly provide neuroimaging ASD
data, therefore these two resources are positioned close to each other.
The 33 identified resources are presented in two separate tables (18 resources in Table 2
and 15 resources in Table 3) based broadly on the category of data type that the resources
hold. The resources in Table 2 contain various types of data including phenotypic data,
neuroimaging data, biospecimens, brain connectivity matrices, and brain statistical maps.
The table also includes data providers that offer ASD participant recruitment services
(i.e., ASD-UK and IAN). Four further resources (i.e., Neuroimaging Informatics Tools
and Resources Clearinghouse—Image Repository, the LONI Image and Data Archive,
COINS Data Exchange, Neuroinformatics Database, Longitudinal Online Research and
Imaging System) were identified but were omitted due to them providing overlapping
ASD datasets from the same source: ABIDE datasets. Therefore, only the ABIDE website
(fcon_1000.projects.nitrc.org/indi/abide) is included in Table 2.
As can be seen in Table 2, data size and participant numbers vary among the resources
and data modalities. Moreover, certain resources provide data from large scale studies
such as data from SFARI and ABIDE, where all participants take part in the same
protocol, whereas other resources such as NDAR and Dryad provide data from very
small studies, e.g., studies containing data from 2, 12, 13 and 34 participants with ASD.
Additionally, some resources are based on initiatives and collaborations that aimed to
collect primary data (not from prior studies) for the purpose of sharing it to the scientific
community. For example, AED is a resourcewith EEGdata fromover 20,000 patient records
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Table 2 A comprehensive list of ASD data resources.
URL Resource Data type category Data type Number of participants with ASD
ndar.nih.gov National Database for
Autism Research (NDAR)a
Phenotypic, neuroimaging,
genetic, omics
Phenotypic, neuroimaging, genetic,
omics data
Over 80,203 participants (however
this number includes the control
participants of the ASD studies).
sfari.org Simons Foundation
Autism Research Initiative
(SFARI)a
Phenotypic, neuroimaging,
genetic
Phenotypic data, biospecimens,
genetic data, neuroimaging data,
participant recruitment (to recruit
SSC families for additional studies)
Over 3,000 participants (SSC), over
200 participants (Simons VIP),
50,000b participants (SPARK).
research.agre.org/program/
descr.cfm
Autism Genetic Resource
Exchange (AGRE)a
Phenotypic, genetic,
biospecimens
Phenotypic data; genetic data,
biospecimens
Over 1,700 families with over 3,300
ASD participants.
iancommunity.org/cs/for_
researchers
Interactive Autism
Network (IAN)a
ASD participant
recruitment services
Phenotypic data, ASD participant
recruitment services
Over 17,000 participants.
asd-uk.com Autism Spectrum
Database-UK (ASD-UK)a
ASD participant
recruitment services
Phenotypic data, ASD participant
recruitment services
Over 3,000 families.
autismbrainnet.org Autism BrainNet BioBank Postmortem brain and related
biospecimens
Over 25 donations (since 2014).b
fcon_1000.projects.nitrc.
org/indi/abide
Autism Brain Imaging Data
Exchange (ABIDE)
Neuroimaging Resting state functional magnetic
resonance imaging (R-fMRI),
structural MRI, phenotypic data
539 participants (ABIDE I),
487 participants (ABIDE II).
– Australian EEG Database
(AED)c
Neuroimaging EEG data 50 participants.d
Brainmap.org BrainMape Human brain statistical
maps
fMRI, PET, and structural
coordinate-based results (x,y,z)
in Talairach or MNI space
70 results/articles relevant to ASD
functional data (search using
BrainMapWeb).
neurovault.org NeuroVault Human brain statistical
maps
Unthresholded statistical maps,
parcellations, and atlases produced
by MRI and PET studies
Five studies: 277, 60, 50, 13, 218
participants in each study.
umcd.
humanconnectomeproject.
org
USC Multimodal
Connectivity Database
Brain connectivity matrices Brain connectivity matrices of fMRI
and DTI
42 (fMRI) participants, 51 (DTI)
participants.
datadryad.org Dryad General data repository lncRNA, MRI, metabolite, MEG Four studies: two, 34, 12, and 13
participants respectively.
figshare.com FigSharee General data repository Phenotypic, statistical, genetic data –
nimhgenetics.org NIMH Repository and
Genomics Resource
(NIMH-RGR)
Biospecimens, genetic Biospecimens (DNA samples and
cell lines, Induced Pluripotent
Stem Cell (iPSC) and Source Cells),
GWAS, genomic sequences
Biospecimens: 4,793 families and
19,359 individuals of which 17,189
have DNA cell lines. Genome-
Wide Association Studies (GWAS)
Data: four studies (1,232 cases, 739
families, 943 families, 935 families).
Sequence data (exome): 2,119 cases.
(continued on next page)
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Table 2 (continued)
URL Resource Data type category Data type Number of participants with ASD
bristol.ac.uk/alspac/ Avon Longitudinal Study
of Parents and Children
(ALSPAC)
Phenotypic, clinical,
biospecimens, genetic
Phenotypic, clinical, biospecimens,
genetic (including GWAS, SNPs,
VNTRs, in addition to sequence
data from UK10K project available
via EGA), ALPAC data linked with
data (e.g., routine health and so-
cial records) from external sources,
bespoke dataf
96 participants (as identified via
follow up questionnaires completed
by carers for when the proband was
nine years old).
catalog.coriell.org Coriell BioRepositories
(including Autism Re-
search Resource)
BioBank Cell cultures, DNA samples, and
induced pluripotent stem cells
158 ASD cases.
neurobiobank.nih.gov NIH NeuroBioBank (NBB) BioBank Postmortem brain and related
biospecimens
64 ASD cases. 22 ASD suspected.
kcl.ac.uk/ioppn/depts/
bcn/Our-research/
Neurodegeneration/brain-
bank.aspx
Medical Research Council
London Neurodegenerative
Diseases Brain Bank
BioBank Postmortem brain and spinal cord
tissue
Four ASD cases.
Notes.
aData-type is described in more detail in File S1.
bThe data is not yet available: It is intended to be available in a future date according to the SFARI website.
cThere is no website or portal for the AED resource; however, the data is available via email requests to aed@newcastle.edu.au.
dThe approximate number of ASD participants was found via email correspondence with aed@newcastle.edu.au.
eAccurate information regarding the approximate number of participants with ASD is not readily available on the website, due to the nature of the search functionality.
fData specifically from ASD participants are not necessarily available in all the different data types described in this table (therefore further specific enquiries directed to the ALSPAC team is advised).
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Table 3 Genetics and omics data resources either from individuals with ASD or containing data relevant to the study of ASD.a
URL Resourcea Data type category Data type Notes
mss.ng MSSNG Genetic/Genomic Phenotypic, genomic (whole genome
sequencing of blood DNA)
10,000 participants. However, data
from only 3,000 probands is currently
available.
gene.sfari.org Simons Foundation Autism
Research Initiative Gene
(SFARI Gene)
Gene Catalogue Animal Model, Protein Interaction
(PIN), Gene Scoring, CNV
An up-to-date, manually annotated
reference set of ASD-linked genes.
projects.tcag.ca/autism Autism Chromosome
Rearrangement Database
(ACRD)
Gene Catalogue Genomic structural variation data—
CNVs
A curated catalogue of structural
variation related to ASD extracted
from publicly available literature and
unpublished data.
autismkb.cbi.pku.edu.cn/
index.php
Autism Knowledgebase
(AutismKB)
Gene Catalogue A collection of genes and variations
associated with ASD with annotations
–
ncbi.nlm.nih.gov/guide/
sitemap/
National Center for
Biotechnology Information
(NCBI)
Genetics, omics A collection of multiple resources—
omics and sequencing data
–
ebi.ac.uk/services/all European Molecular
Biology Laboratory
(EMBL-EBI)
Genetics, omics A collection of multiple resources—
omics and sequencing data
–
uniprot.org Universal Protein Resource
(UniProt)
Protein sequences Protein sequences and their
annotations
Can be found among EMBL-EBI
resources. 91 (reviewed) and
346 (unreviewed) protein records
associated with ASD.
ebi.ac.uk/ega The European Genome-
phenome Archive (EGA)
Omics—Functional
genomics
Interaction of genotype and
phenotype (including data from
UK10K project)
Can be found among EMBL-EBI
resources.
thebiogrid.org Biological General
Repository for Interaction
Datasets (BioGRID)
Omics Genetic and protein interaction data Resource that archives and
disseminates genetic and protein
interaction data.
gpmdb.thegpm.org/index.
html
Global Proteome Machine
Database (GPM DB)
Omics—Proteomics Proteomics data from tandem mass
spectrometry
Open-source system for analyzing,
storing, and validating proteomics
information derived from tandem
mass spectrometry.
peptideatlas.org PeptideAtlas Omics—Proteomics Peptide sequences, mapping—
proteome information/data
A collection of peptides identified in a
large set of tandem mass spectrometry
proteomics experiments.
ddbj.nig.ac.jp/index-e.html DNA DataBank of Japan
(DDBJ)
DNA and RNA
sequences
DNA and RNA sequences Annotated collection of all publicly
available nucleotide sequences and
their translated amino acid sequences.
(continued on next page)
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Table 3 (continued)
URL Resourcea Data type category Data type Notes
chr7.org The Chromosome 7
Annotation Project
DNA sequences DNA sequence and annotation of the
entire human chromosome 7
84 cases.
mirbase.org miRBase: the microRNA
database
miRNA sequences miRNA sequences and annotation –
gbrowse.csbio.unc.edu/cgi-
bin/gb2/gbrowse/slep
Sullivan Lab Evidence
Project (SLEP)
Genetics, omics A collection of genes and variations
associated with ASD with annotations
Findings from genome wide link-
age (GWL), genome wide association
(GWA), and microarray (MA) studies
for ASD.
Notes.
aThe resources listed in this table contain data either from individuals with ASD or data relevant to ASD research that is collected from non-affected individuals (e.g., from individuals with certain genetic
profiles or syndromes related to ASD research).
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(however only 50 ASD EEG records) made available through the collaboration between
John Hunter Hospital and the University of Newcastle, Australia.
The data types of the resources in Table 3 are somewhat more homogenous and would
fall under the categories of genomic, genetic, and omics/proteomics data. For example,
data types include gene catalogue (e.g., CNVs and protein interactions), sequencing data
(e.g., DNA sequencing, RNA sequencing, and protein sequencing), functional genomics
data (interaction of genotype and phenotype), genetic and protein interaction data, in
addition to other genetic and omics data. The relevant data from these resources are either
genetic or omics data shown to be potentially involved with ASD (collected from unaffected
participants) or data from participants with ASD. Several resources, namely, NDAR, SFARI,
AGRE, and NIMH Repository and Genomics Resource, also provide various genetic data,
however these resources are grouped with the resources in Table 2 because they also provide
additional data-types such as phenotypic, neuroimaging, and/or biospecimens.
Some of the resources in Tables 2 and 3 such as NDAR, SFARI, AGRE, and MSSNG, are
specialized in ASD data and aim to share only autism-related data. While other resources,
due to the purpose of the resource or the nature of the data, aim to share data involved
with numerous populations and conditions. Nevertheless, these resources also housed data
involved with ASD research. Examples of non-ASD specialized resources include Coriell
BioRepositories and Universal Protein Resources. The resources vary in the way the data
is described or made viewable, searchable, and accessible for researchers. For example,
different informatics portals or systems (see the ‘URL’ columns in Tables 2 and 3, and/or
the metadata articles in File S1) are used to achieve the task of data sharing.
NDAR, SFARI, AGRE, MSSNG, IAN, and ASD-UK are among the key resources which
provide ASD data. NDAR (Hall et al., 2012) is the largest ASD resource housing ASD
data of various types from numerous sources. It is a US NIH-funded initiative that aims
to ‘‘accelerate progress in ASD research through data sharing, data harmonization, and
the reporting of research results’’ (ndar.nih.gov). NDAR shares various types of data:
phenotypic data (e.g., clinical and diagnostic assessments such as the Autism Diagnostic
Inventory (ADI) and ADOS); neuroimaging data (e.g., MEG, fMRI, and DTI); genetic
and omics data (e.g., DNA (Microarray and Sequencing) and RNA (Microarray and
Sequencing)) related to human participants. NDAR is evolving and it is now incorporated
under the NIMH Data Archive (data-archive.nimh.nih.gov). Researchers can access the
data without any fees, however they need to first request and gain approval for access
(see Payakachat, Tilford & Ungar, 2016, for a flow diagram for data access). The NDAR
system enables data to be aggregated not only from other major data resources (e.g., SFARI,
AGRE, and IAN), but also from qualified autism researchers regardless of funding source.
Currently, NDAR contains data from over 80,000 participants (however this number
includes neurotypical control participants of the ASD studies).
SFARI is an ASD data resource that shares very well-characterized participant data due
to the rigorous standardization and coordination among the SFARI-funded investigators
(currently over 250 investigators). SFARI’s aim is to ‘‘improve the understanding, diagnosis
and treatment of autism spectrum disorders by funding innovative research of the highest
quality and relevance’’ (sfari.org/about-sfari). SFARI also aims ‘‘to facilitate and drive
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research in the field as a whole’’ through granting data access to autism researchers
(regardless of their funding source). Approved researchers are granted access to the data
without a fee, however biospecimen data is available on a modest fee-for use basis. SFARI’s
data are segmented and collected from three large cohorts: Simons Simplex Collection
(SSC), Simons Variation in Individuals Project (Simons VIP), and Simons Foundation
Powering Autism Research for Knowledge (SPARK). The SSC is intended to be especially
useful for investigating de novo (new) mutations due to the cohort comprising of nearly
3,000 simplex families. Simons VIP contains data from over 200 participants with recurrent
genetic variants involved with ASD (i.e., deletion and duplication of chromosomal region
16p11.2 and 1q21.1). SPARK is a new initiative involving collecting phenotypic and
biospecimen data from 50,000 participants with ASD. This initiative will later provide
researchers with participant recruitment services through retaining a database of the
SPARK participants who consent to be re-contacted for future studies.
AGRE is a resource that is mainly supported by Autism Speaks and is among the leading
resources committed to advancing ASD genetic research. AGRE shares phenotypic (e.g.,
ADI-R and ADOS), genetic (e.g., high-density SNP and Genome Wide Association Study
data), and biospecimen data (e.g., cell lines, DNA and plasma) of over 1,700 well defined
multiplex and simplex families with over 3,300 participants with ASD. AGRE can also
provide participant recruitment services. In order to access data, researchers need to
request data and pay per sample fee for obtaining biospecimen data.
MSSNG is the largest ASD genomic resource made available to the research community.
It is the outcome of the diverse collaboration efforts between Autism Speaks, SickKids
Hospital, University of Toronto, and Google. MSSNG’s aim is ‘‘to provide the best
resources to enable the identification of many subtypes of autism, which may lead to better
diagnostics, as well as personalized and more accurate treatments’’ (research.mss.ng). The
target is to sequence and share data from whole genome sequencing of blood DNA of
10,000 families affected by ASD. The cohorts consist of AGRE participants, but could
later include other well-phenotyped cohorts. Over 5,000 whole genome sequences (and
coded phenotype data) with nearly 3,000 sequences from participants with ASD are freely
available to approved researchers.
IAN and ASD-UK are both useful resources based in the US and the UK respectively, that
enable the collaboration between researchers and participants. With the aim of facilitating
and advancing ASD research, these resources provide approved researchers with participant
recruitment services and phenotypic data. The data that can be accessed consist of certain
phenotypic data (e.g., Social Communication Questionnaire) along with medical data
(e.g., medical history). Researchers can request and access these resources at a cost. To
date, IAN and ASD-UK registered over 17,000 participants with ASD and over 3,000
families, respectively. For more information on NDAR, SFARI, AGRE, ASD-UK, and IAN
in addition to a list of relevant metadata articles, see File S1.
DISCUSSION
The systematic search showed that there are at least 33 data resources and initiatives that aim
to share available ASD data to interested researchers, and therefore further advance ASD
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research and understanding of its heterogeneity and potential subtypes. These resources
and initiatives have undoubtedly had, and will continue to exert, significant influence
on the field of ASD research. Particularly, notable initiatives such as NDAR and SFARI
can, arguably, have an impact on the nature of ASD research and the process of data
sharing. Although NDAR and SFARI share similar aims, they differ in their approach and
thus affect the field differently. Both resources aim for the advancement of ASD research
through supporting certain ASD projects and facilitating the secondary analysis of data.
Additionally, NDAR and SFARI are specialized ASD resources that aim to accommodate
for ASD-specific data types and methodologies. As a result, these resources led to new
findings and numerous publications in the field. Each resource, however, accomplishes its
aims through a distinctive approach and data sharing process, which arguably differentially
influences the nature of ASD research and data sharing process. Specifically, each resource
adopted a different approach to obtaining its primary data. Even though NDAR and
SFARI initially obtained and shared data collected solely from particular projects that they
funded, NDAR currently obtains its primary data frommultiple sources including over 120
NIH-funded investigators in addition to other autism researchers irrespective of funding
source. SFARI, on the other hand, obtains its primary data only from SFARI-funded
investigators mainly involved in large projects. One approach (i.e., NDAR’s approach)
interacts with various sources that range in the scale of their data, while the other interacts
with sources that offer large datasets. Consequently, the former approach supports the
secondary analysis and sharing of smaller scale data, while the latter drives the reuse of
large datasets and the sharing of large data.
Both approaches have their merits and there are advantages and disadvantages of the
sharing of either small or big data. One advantage of sharing small data is to allow the
scientific community to make use of the rich variety of research data that is collected
by small independent research efforts. As ASD is a clinical population that is typically
challenging to recruit and examine, especially in its more severe form, most ASD studies
therefore are comprised of small sample sizes or small data. Collectively, these small
efforts would make up a large sum of studies, with data from various specialties and
modalities. This can be valuable for secondary analysis if the data is shared, especially if
the datasets can either be analysed individually or integrated into different combinations.
Whether to augment the scale of the dataset or to explore links between data from
different modalities and levels, integrating datasets from different studies is a potentially
greatly beneficial yet challenging task that some data resources are tackling. A model
initiative and collaboration between NDAR and SFARI towards this direction resulted
in the development of a tool that ultimately helps in identifying overlapping data and
in linking data from different studies. The tool is a free software application that assigns
global unique identifiers (GUID) to research participants (see Johnson et al., 2010, GUID
Tool (https://ndar.nih.gov/tools_guid_tool.html), Rudacille, 2010). Using an algorithm
derived from four input variables taken from a participant’s birth certificate, the GUID
tool produces a sequence of letters and numbers to serve as a standardized, unique, and
anonymized code specific to a research participant, regardless of the study the participant is
engaged in. The generated GUID will always be the same for the particular participant and
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thus will be used across studies if the participant participates in more than one study. This
systemwouldmake it possible to trace data across studies of the same participant and would
facilitate data overlap detection, especially if more studies and data resources use GUIDs.
Hence, NDAR requires all prospective studies to include GUIDs in the data submission plan
(and encourages retrospective studies to include GUIDs or pseudo-GUIDs). Other than
NDAR and SFARI, a number of major ASD resources, namely, IAN, AGRE, and Autism
BrainNet generate GUIDs for their studies making GUIDs an even more effective tool.
However, despite these efforts, combining or linking small different datasets remains
a difficult task requiring sophisticated integration tools and the participation and
collaboration of data resources. While in the case of big data, the datasets offered are
large homogenous datasets that although could also benefit from being combined with
other datasets, it is in itself ready for re-analysis with great statistical power. Despite
the challenge of integrating small data, sharing data (in both cases small or big) would
encouragemore transparency and rigorous research, whether because the re-analysis would
uncover limitations or errors not previously identified; or because the prospect of sharing
data, encourages the respective researcher to be more cautious in their analysis and/or
reporting. This can be implied from the findings of a recent report, which found that
psychology studies that were unwilling to share data were associated with weaker statistical
evidence, and more errors in statistical reporting of results in comparison to studies with
shared data (Wicherts, Bakker & Molenaar, 2011).
Other than the impact of the available ASD resources, a second point to consider is the
role of retrospective data and whether it has a role to play towards the shift to big data
and open data. Retrospective data here is referred to data that is previously collected by
researchers, clinicians, or other entities for the purpose of the respective studies or for
keeping medical records and/or other information about patients or groups of interest.
Naturally, there is a large sum of ASD retrospective data whether cumulatively from
small independent studies or from clinical sources with many records and information.
Although invaluable for the advancement of ASD research and for medical purposes, this
type of data is collected without taking into account the prospect of sharing it. If shared,
this ASD data can be used by researchers for secondary or primary analysis, respectively.
However, the sharing of data that is not initially prepared for the purpose of sharing can
be challenging and the available data-sharing resources lack initiatives that address this
challenge. The resources should tailor to retrospective data and aim to integrate and present
annotated ASD data that later gained permissions for sharing. NDAR along with some
EEG-specialized and general-purpose resources, such as AED, Dryad, and FigShare, among
others, allow for the sharing of certain retrospective data, however tailored resources that
cater to retrospective data from various sources and modalities is still limited.
A third point to consider is the difficulty of finding certain ASD data and sufficient data
annotation that are of interest to researchers. As shown in Tables 2 and 3, and the File S1,
data from certain modalities are underrepresented or even lacking. For example, none of
the available resources provide access to eye-tracking data obtained from participants with
ASD. In addition, very few resources provide EEG or MEG data obtained from participants
with ASD: despite the large number of datasets being held by NDAR, no EEG datasets
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and only 21 MEG datasets are available from individuals with ASD. Even when this type
of data (or neuroimaging data generally) is found, researchers face other difficulties in
finding certain information about the data. One bit of data information that is essential to
researchers is pertaining to the level of data quality (both the raw and processed data) in
accordance with the standards of the specific field and modality type. However, a system
that describes quality is not developed and the data-sharing process, typically, does not
permit researchers to have a quick view of the actual data. If data can be viewed (before
it is officially obtained), researchers would be better able to determine the quality and
feasibility of the data in relation to the researchers’ interests, skills, and resources. The
available ASD data websites either describe or display the available data (or both), however
it can be challenging at times to find specific information relating to sample size and other
details about the data. For example, it is unclear in certain cases whether the mentioned
sample size, relating to an available dataset, is that of solely participants with ASD or
whether it is inclusive of control participants. Furthermore, information about the data
that will be shared from on-going studies is very limited if at all reported. Generally,
although the current data-websites describe or annotate the data in a certain way, further
comprehensive and clear annotation is necessary along with a better inclusion of data from
different modalities.
CONCLUDING REMARKS
Here, we have identified 33 resources that provide data obtained from individuals with
ASD to the research community. While we are confident that we have identified the vast
majority, if not all, of the publically available data sources that provide behavioural and
neuroimaging data from individuals with ASD, we may not have captured some resources
in the cases where research groups have data that they are willing to share, but did not
publicize the data in a way that was identifiable via our key-word search. The resources
and data-websites are not static: they are improving and the number of available data
is increasing in size and variety. Notably, the drive for big data, sharing data, and for
accelerating research on complex heterogeneous disorders such as autism is not only
leading to the on-going growth of current initiatives, but also of the development of new
ones, e.g., MSSNG.
ADDITIONAL INFORMATION AND DECLARATIONS
Funding
The authors received no funding for this work.
Competing Interests
The authors declare there are no competing interests.
Author Contributions
• Reem Al-jawahiri conceived and designed the experiments, performed the experiments,
analyzed the data, wrote the paper, prepared figures and/or tables.
• Elizabeth Milne conceived and designed the experiments, reviewed drafts of the paper.
Al-jawahiri and Milne (2017), PeerJ, DOI 10.7717/peerj.2880 16/21
Data Availability
The following information was supplied regarding data availability:
The sources of the raw data evaluated are listed in the article.
Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/
peerj.2880#supplemental-information.
REFERENCES
American PA, American Psychiatric Association Task Force ODSM, American Psy-
chiatric Association DSMIVTF, Apa APA, Asociación Psiquiátrica A, Asociación
Americana DP, Joint Information Service of the American Psychiatric Association
and the National Association for MH, AmericanMedico-Psychological A, Ameri-
can Psychiatric Institute for Research AE. 2013.Diagnostic and statistical manual of
mental disorders DSM-5. 5th edition. Arlington: American Psychiatric Association,
c2013.
Ausderau KK, FurlongM, Sideris J, Bulluck J, Little LM,Watson LR, Boyd BA, Belger
A, Dickie VA, Baranek GT. 2014. Sensory subtypes in children with autism spectrum
disorder: latent profile transition analysis using a national survey of sensory features.
Journal of Child Psychology and Psychiatry and Allied Disciplines 55(8):935–944
DOI 10.1111/jcpp.12219.
Banerjee-Basu S, Packer A. 2010. SFARI Gene: an evolving database for the autism
research community. Disease Models & Mechanisms 3(3–4):133–135
DOI 10.1242/dmm.005439.
Bishop S, Hus V, Duncan A, Huerta M, GothamK, Pickles A, Kreiger A, Buja A, Lund
S, Lord C. 2013. Subcategories of restricted and repetitive behaviors in children
with autism spectrum disorders. Journal of Autism and Developmental Disorders
43(6):1287–1297 DOI 10.1007/s10803-012-1671-0.
Buxbaum JD, Silverman JM, Smith CJ, Kilifarski M, Reichert J, Hollander E, Lawlor
BA, Fitzgerald M, Greenberg DA, Davis KL. 2001. Evidence for a susceptibility gene
for autism on chromosome 2 and for genetic heterogeneity. The American Journal of
Human Genetics 68(6):1514–1520 DOI 10.1086/320588.
Chang YS, Owen JP, Pojman NJ, Thieu T, Bukshpun P,WakahiroMLJ, Marco EJ,
Berman JI, Spiro JE, ChungWK, Buckner RL, Roberts TPL, Nagarajan SS, Sherr
EH, Mukherjee P. 2016. Reciprocal white matter alterations due to 16p11.2 chro-
mosomal deletions versus duplications. Human Brain Mapping 37(8):2833–2848
DOI 10.1002/hbm.23211.
Chaste P, Klei L, Sanders SJ, Hus V, MurthaMT, Lowe JK,Willsey AJ, Moreno-De-
Luca D, Yu TW, Fombonne E, Geschwind D, Grice DE, Ledbetter DH,Mane SM,
Martin DM,Morrow EM,Walsh CA, Sutcliffe JS, Lese Martin C, Beaudet AL,
Lord C, State MW, Cook EH, Devlin B. 2015. A genome-wide association study of
autism using the Simons simplex collection: does reducing phenotypic heterogeneity
Al-jawahiri and Milne (2017), PeerJ, DOI 10.7717/peerj.2880 17/21
in autism increase genetic homogeneity? Biological Psychiatry 77(9):775–784
DOI 10.1016/j.biopsych.2014.09.017.
Cholemkery H, Medda J, Lempp T, Freitag CM. 2016. Classifying autism spectrum dis-
orders by ADI-R: subtypes or severity gradient? Journal of Autism and Developmental
Disorders 46(7):2327–2339 DOI 10.1007/s10803-016-2760-2.
Consortium SV. 2012. Simons Variation in Individuals Project (Simons VIP): a genetics-
first approach to studying autism spectrum and related neurodevelopmental
disorders. Neuron 73(6):1063–1067 DOI 10.1016/j.neuron.2012.02.014.
Cummings JA, Zagrodney JM, Day TE. 2015. Impact of open data policies on consent to
participate in human subjects research: discrepancies between participant action and
reported concerns. PLOS ONE 10(5):e0125208 DOI 10.1371/journal.pone.0125208.
Doshi-Velez F, Ge Y, Kohane I. 2014. Comorbidity clusters in autism spectrum
disorders: an electronic health record time- series analysis. Pediatrics 133(1):e54
DOI 10.1542/peds.2013-0819.
Eickhoff S, Nichols TE, Van Horn JD, Turner JA. 2016. Sharing the wealth: neuroimag-
ing data repositories. NeuroImage 124:1065–1068
DOI 10.1016/j.neuroimage.2015.10.079.
Ferguson AR, Nielson JL, CraginMH, Bandrowski AE, MartoneME. 2014. Big data
from small data: data- sharing in the ‘long tail’ of neuroscience. Nature Neuroscience
17(11):1442–1447 DOI 10.1038/nn.3838.
Focus on Big Data. 2014. Focus on big data. Nature Neuroscience 17(11):1429
DOI 10.1038/nn.3856.
Fountain C,Winter AS, Bearman PS. 2012. Six developmental trajectories characterize
children with autism. Pediatrics 129(5):e112–e120 DOI 10.1542/peds.2011-1601.
Georgiades S, Szatmari P, Boyle M, Hanna S, Duku E, Zwaigenbaum L, Bryson S,
Fombonne E, Volden J, Mirenda P, Smith I, RobertsW, Vaillancourt T,Waddell
C, Bennett T, Thompson A. 2013. Investigating phenotypic heterogeneity in
children with autism spectrum disorder: a factor mixture modeling approach.
Journal of Child Psychology and Psychiatry and Allied Disciplines 54(2):206–215
DOI 10.1111/j.1469-7610.2012.02588.x.
Geschwind DH, Levitt P. 2007. Autism spectrum disorders: developmental dis-
connection syndromes. Current Opinion in Neurobiology 17(1):103–111
DOI 10.1016/j.conb.2007.01.009.
GothamK, Pickles A, Lord C. 2012. Trajectories of autism severity in children using
standardized ADOS scores. Pediatrics 130(5):e1278 DOI 10.1542/peds.2011-3668.
Greaves-Lord K, EussenM, Verhulst F, Minderaa R, MandyW, Hudziak J, Steen-
huis M, Nijs P, Hartman C. 2013. Empirically based phenotypic profiles of
children with pervasive developmental disorders: interpretation in the light of
the DSM- 5. Journal of Autism and Developmental Disorders 43(8):1784–1797
DOI 10.1007/s10803-012-1724-4.
Hall D, Huerta M, McAuliffe M, Farber G. 2012. Sharing heterogeneous data: the na-
tional database for autism research. Neuroinform 10(4):331–339
DOI 10.1007/s12021-012-9151-4.
Al-jawahiri and Milne (2017), PeerJ, DOI 10.7717/peerj.2880 18/21
Hanson E, Bernier R, Porche K, Jackson FI, Goin-Kochel RP, Snyder LG, Snow AV,
Wallace AS, Campe KL, Zhang Y, Chen Q, D’Angelo D, Moreno-De-Luca A, Orr
PT, Boomer KB, Evans DW, Kanne S, Berry L, Miller FK, Olson J. 2015. The cogni-
tive and behavioral phenotype of the 16p11.2 deletion in a clinically ascertained pop-
ulation. Biological Psychiatry 77(9):785–793 DOI 10.1016/j.biopsych.2014.04.021.
Happé F, Ronald A, Plomin R. 2006. Time to give up on a single explanation for autism.
Nature Neuroscience 9(10):1218–1220 DOI 10.1038/nn1770.
Hewitson L. 2013. Scientific challenges in developing biological markers for autism. OA
Autism 1(1):7.
HuVW, Steinberg ME. 2009. Novel clustering of items from the Autism Diagnostic
Interview-Revised to define phenotypes within autism spectrum disorders. Autism
Research 2(2):67–77 DOI 10.1002/aur.72.
Hudac CM, Kresse A, Aaronson B, Deschamps TD,Webb SJ, Bernier RA. 2015.
Modulation of mu attenuation to social stimuli in children and adults with 16p11.2
deletions and duplications. Journal of Neurodevelopmental Disorders 7(1):25
DOI 10.1186/s11689-015-9118-5.
Hus V, Pickles A, Cook EH, Risi S, Lord C. 2007. Using the autism diagnostic
interview—revised to increase phenotypic homogeneity in genetic studies of autism.
Biological Psychiatry 61(4):438–448 DOI 10.1016/j.biopsych.2006.08.044.
Jenkins J, Chow V, Blaskey L, Kuschner E, Qasmieh S, Gaetz L, Edgar JC, Mukherjee
P, Buckner R, Nagarajan SS, ChungWK, Spiro JE, Sherr EH, Berman JI, Roberts
TPL. 2016. Auditory evoked M100 response latency is delayed in children with
16p11.2 deletion but not 16p11.2 duplication. Cerebral Cortex 26(5):1957–1964
DOI 10.1093/cercor/bhv008.
Johnson SB,Whitney G, McAuliffe M,Wang H, McCreedy E, Rozenblit L, Evans CC.
2010. Using global unique identifiers to link autism collections. Journal of the Ameri-
can Medical Informatics Association 17(6):689–695 DOI 10.1136/jamia.2009.002063.
Kim SH,Macari S, Koller J, Chawarska K. 2016. Examining the phenotypic hetero-
geneity of early autism spectrum disorder: subtypes and short- term outcomes.
Journal of Child Psychology and Psychiatry and Allied Disciplines 57(1):93–102
DOI 10.1111/jcpp.12448.
Lai MC, LombardoMV, Chakrabarti B, Baron-Cohen S. 2013. Subgrouping the
autism ‘‘spectrum’’: reflections on DSM-5. PLOS Biology 11(4):e1001544
DOI 10.1371/journal.pbio.1001544.
Leblanc J, Nelson C. 2016. Deletion and duplication of 16p11.2 are associated with
opposing effects on visual evoked potential amplitude.Molecular Autism 7:30
DOI 10.1186/s13229-016-0095-7.
Liu X-Q, Georgiades S, Duku E, Thompson A, Devlin B, Cook EH,Wijsman EM, Pater-
son AD, Szatmari P. 2011. Identification of genetic loci underlying the phenotypic
constructs of autism spectrum disorders. Journal of the American Academy of Child
and Adolescent Psychiatry 50(7):687–696 DOI 10.1016/j.jaac.2011.05.002.
Al-jawahiri and Milne (2017), PeerJ, DOI 10.7717/peerj.2880 19/21
Liu X, Paterson AD, Szatmari P. 2008. Genome-wide linkage analyses of quantitative
and categorical autism subphenotypes. Biological Psychiatry 64(7):561–570
DOI 10.1016/j.biopsych.2008.05.023.
Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, ShagoM,Moessner
R, Pinto D, Ren Y, Thiruvahindrapduram B, Fiebig A, Schreiber S, Friedman
J, Ketelaars CEJ, Vos YJ, Ficicioglu C, Kirkpatrick S, Nicolson R, Sloman L,
Summers A, Gibbons CA, Teebi A, Chitayat D,Weksberg R, Thompson A, Vardy
C, Crosbie V, Luscombe S, Baatjes R, Zwaigenbaum L, RobertsW, Fernan-
dez B, Szatmari P, Scherer SW. 2008. Structural variation of chromosomes in
autism spectrum disorder. American Journal of Human Genetics 82(2):477–488
DOI 10.1016/j.ajhg.2007.12.009.
Oliver JM, Slashinski MJ, Wang T, Kelly PA, Hilsenbeck SG, McGuire AL. 2012. Bal-
ancing the risks and benefits of genomic data sharing: genome research participants’
perspectives. Public Health Genomics 15(2):106–114 DOI 10.1159/000334718.
Payakachat N, Tilford J, UngarW. 2016. National Database for Autism Research
(NDAR): big data opportunities for health services research and health technology
assessment. Pharmacoeconomics 34(2):127–138 DOI 10.1007/s40273-015-0331-6.
Poldrack R, Gorgolewski K. 2014.Making big data open: data sharing in neuroimaging.
Nature Neuroscience 17(11):1510–1517 DOI 10.1038/nn.3818.
Qureshi AY, Mueller S, Snyder AZ, Mukherjee P, Berman JI, Roberts TPL, Na-
garajan SS, Spiro JE, ChungWK, Sherr EH, Buckner RL. 2014. Opposing
brain differences in 16p11.2 deletion and duplication carriers. The Journal of
Neuroscience: the Official Journal of the Society for Neuroscience 34(34):11199
DOI 10.1523/JNEUROSCI.1366-14.2014.
Rudacille D. 2010. Researchers debut unique identifiers for study participants. Available
at https:// spectrumnews.org/news/ researchers-debut-unique-identifiers-for-study-
participants/ (accessed on 21 October 2016).
Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C,Walsh T, Yamrom B, Yoon
S, Krasnitz A, Kendall J, Leotta A, Pai D, Zhang R, Lee Y-H, Hicks J, Spence SJ,
Lee AT, Puura K, Lehtimäki T, Ledbetter D, Gregersen PK, Bregman J, Sutcliffe
JS, Jobanputra V, ChungW,Warburton D, KingM-C, Skuse D, Geschwind DH,
Gilliam TC, Ye K,Wigler M. 2007. Strong association of de novo copy number
mutations with autism. Science 316(5823):445–449 DOI 10.1126/science.1138659.
Shao Y, CuccaroML, Hauser ER, Raiford KL, MenoldMM,Wolpert CM, Ravan SA,
Elston L, Decena K, Donnelly SL, Abramson RK,Wright HH, Delong GR, Gilbert
JR, Pericak-VanceM. 2003. Fine mapping of autistic disorder to chromosome
15q11- q13 by use of phenotypic subtypes. American Journal of Human Genetics
72(3):539–548 DOI 10.1086/367846.
Simons Foundation. 2016. Publications resulting from the Simons VIP. Available at
https:// sfari.org/ resources/autism-cohorts/ simons-vip/publications-resulting-from-
the-simons-vip.
Steinman KJ, Spence SJ, Ramocki MB, ProudMB, Kessler SK, Marco EJ, Green
Snyder L, Angelo D, Chen Q, ChungWK, Sherr EH. 2016. 16p11.2 deletion
Al-jawahiri and Milne (2017), PeerJ, DOI 10.7717/peerj.2880 20/21
and duplication: characterizing neurologic phenotypes in a large clinically ascer-
tained cohort. American Journal of Medical Genetics Part A 170(11):2943–2955
DOI 10.1002/ajmg.a.37820.
Stessman HA, Bernier R, Eichler EE. 2014. A genotype-first approach to defining the
subtypes of a complex disease. Cell 156(5):872–877 DOI 10.1016/j.cell.2014.02.002.
Stessman HA, Turner TN, Eichler EE. 2016.Molecular subtyping and improved treat-
ment of neurodevelopmental disease. Genome Medicine 8(1):22
DOI 10.1186/s13073-016-0278-z.
Uljarević M, Lane A, Kelly A, Leekam S. 2016. Sensory subtypes and anxiety in
older children and adolescents with autism spectrum disorder. Autism Research
9(10):1073–1078 DOI 10.1002/aur.1602.
VanHorn JD, Scott TG, Rockmore D, Michael SG. 2004. Sharing neuroimaging studies
of human cognition. Nature Neuroscience 7(5):473–481 DOI 10.1038/nn1231.
VanHorn JD, Toga AW. 2009. Is it time to re- prioritize neuroimaging databases and
digital repositories? NeuroImage 47(4):1720–1734
DOI 10.1016/j.neuroimage.2009.03.086.
VanHorn JD,Wolfe J, Agnoli A, Woodward J, Schmitt M, Dobson J, Schumacher
S, Vance B. 2005. Neuroimaging databases as a resource for scientific discovery.
International Review of Neurobiology 66:55–87 DOI 10.1016/S0074-7742(05)66002-3.
Veatch OJ, Veenstra-vanderweele J, Potter M, Pericak-vance MA, Haines JL. 2014.
Genetically meaningful phenotypic subgroups in autism spectrum disorders. Genes,
Brain and Behavior 13(3):276–285 DOI 10.1111/gbb.12117.
Venker CE, Ray-Subramanian C, Bolt DM,Weismer SE. 2014. Trajectories of
autism severity in early childhood. Journal of Autism and Developmental Disorders
44(3):546–563 DOI 10.1007/s10803-013-1903-y.
Vieland V, Hallmayer J, Huang Y, Pagnamenta A, Pinto D, Khan H, Monaco A,
Paterson A, Scherer S, Sutcliffe J, Szatmari P. 2011. Novel method for combined
linkage and genome- wide association analysis finds evidence of distinct genetic
architecture for two subtypes of autism. Journal of Neurodevelopmental Disorders
3(2):113–123 DOI 10.1007/s11689-011-9072-9.
Werling DM, Geschwind DH. 2013. Sex differences in autism spectrum disorders.
Current Opinion in Neurology 26(2):146–153 DOI 10.1097/WCO.0b013e32835ee548.
Wicherts JM, Bakker M, Molenaar D. 2011.Willingness to share research data is related
to the strength of the evidence and the quality of reporting of statistical results
(reproducibility of reported p-values in psychology). PLOS ONE 6(11):e26828
DOI 10.1371/journal.pone.0026828.
Wiggins LD, Robins DL, Adamson LB, Bakeman R, Henrich CC. 2012. Support for a
dimensional view of autism spectrum disorders in toddlers. Journal of Autism and
Developmental Disorders 42(2):191–200 DOI 10.1007/s10803-011-1230-0.
Al-jawahiri and Milne (2017), PeerJ, DOI 10.7717/peerj.2880 21/21
